Application Note

Vapor Phase Hydrogen Peroxide

Source: STERIS Corporation

Sterile products which are not terminally sterlized, and therefore are aseptically produced, need to be tested to assure their sterility prior to release for shipment. This sterlity testing occurs in a controled environment where the product is removed from its container and tested through various methods for microbial contamination. If the aseptic process has not been compromised, the product should yield no growth for microbes, and the product may be released for shipment. If, however, the test shows a positive growth, then release of the product may be delayed while additional testing takes place or, worse, the entire lot may be scrapped. For this reason it is important that the environment where the testing is being done does not contaminate the testing process.

Benefits

  • Reduction Of Potential False Positives
    Typically, 0.25% of lots tested result in false positives. That's 1 out of every 400 lots tested. Isolators can almost eliminate the false positives.
  • Improved Biodecontamination
    Using the VHP 1000 to decontaminate an isolator can result in reductions of 10-6 in microbial content.
  • Improved Throughput
    By reducing false positive occurrences, product is available for shipment immediately after successful testing.

 

access the Application Note!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online